Altogether, our data suggest that HIF-P4H-1 inhibition enhances reciprocal negative regulation of the NF-κB and p53 pathways and may be a promising therapeutic candidate for inflammatory diseases and cancer. This evidence concerns the gene NFKB1 and cancer.